Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Multiple Myeloma 5Recurrence 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Gemcitabine 5Capecitabine 4pembrolizumab 3Fluorouracil 3Cisplatin 3vinflunine 2enzalutamide 2cabazitaxel 2abiraterone 2Ipilimumab 2Haloperidol 2Androgen Antagonists 2vedolizumab 1trifluridine tipiracil drug combination 1relugolix 1racemetyrosine 1nimotuzumab 1nilutamide 1lanreotide 1histrelin 1futibatinib 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1bicalutamide 1beta-Glucans 1auricularum 1atezolizumab 1apatinib 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × Lenalidomide × Clear all
NCT00055562 2005-06-24

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Celgene

Phase 2/3 Completed
274 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡